Drug:
IMITREX 50-mg
Side effects: (15)
nausea
vomiting
dizziness
drowsiness
feeling sick
wheezing
tightness in the jaw
neck
chest
chest pain
heart throbbing
shortness of breath
swelling of the eyelids, face, or lips,
develop a skin rash
hives
Precautions: (12)
General
Chest discomfort and wjaw or neck tightness have been reported following use of sumatriptan succinate tablets and have also been reported infrequently following administration of sumatriptan nasal spray. Chest, jaw, or neck tightness is relatively common after administration of sumatriptan succinate injection. Only rarely have these symptoms been associated with ischemic ECG changes. However, because sumatriptan may cause coronary artery vasospasm, patients who experience signs or symptoms suggestive of angina following sumatriptan should be evaluated for the presence of CAD or a predisposition to Prinzmetal's variant angina before receiving additional doses of sumatriptan, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud's syndrome following sumatriptan should be evaluated for atherosclerosis or predisposition to vasospasm
Sumatriptan succinate should also be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs, such as impaired hepatic or renal function.
There have been rare reports of seizure following administration of sumatriptan. Sumatriptan should be used with caution in patients with a history of epilepsy or structural brain lesions that lower their seizure threshold.
Care should be taken to exclude other potentially serious neurologic conditions before treating headache in patients not previously diagnosed with migraine headache or who experience a headache that is atypical for them. There have been rare reports where patients received sumatriptan for severe headaches that were subsequently shown to have been secondary to an evolving neurologic lesion.
For a given attack, if a patient does not respond to the first dose of sumatriptan, the diagnosis of migraine should be reconsidered before administration of a second dose.
Source:
Both sources are © copyright material and are from these links
http://www.migrainehelp.com/4.about_imitrex/4.2.taking_imitrex/4.2.2.imitrex_tablets.html